Registered title, quoted from ClinicalTrials.gov
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Shandong Cancer Hospital and Institute; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06690216, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pathologically confirmed malignant tumors, including:
Inclusion criterion 3
Detectable PD-L1 expression in tumor tissue (based on immunohistochemistry or biopsy).
Inclusion criterion 8
Unstable angina or congestive heart failure (NYHA class ≥ 2).
Exclusion criterion 6
ECOG performance status of 0-1.
Inclusion criterion 10
No contraindications to [18F]AlF-NOTA-PCP2 PET/CT imaging.
Inclusion criterion 11
Pregnant or breastfeeding women.
Exclusion criterion 3
Women of childbearing potential without a negative pregnancy test prior to study entry.
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06690216, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Signed informed consent obtained.
- Age ≥ 18 years, any gender.
- Pathologically confirmed malignant tumors, including:
- Glioblastoma
- Head and neck squamous cell carcinoma
- Non-small cell lung cancer
- Esophageal cancer
- Detectable PD-L1 expression in tumor tissue (based on immunohistochemistry or biopsy).
- Measurable disease with at least one residual tumor lesion.
- ECOG performance status of 0-1.
- No contraindications to [18F]AlF-NOTA-PCP2 PET/CT imaging.
- Willing and able to comply with study procedures and follow-up visits.
Exclusion Criteria:
- Participation in another interventional clinical trial.
- Failure to recover from toxic effects or complications of prior interventions (≤ grade 1 or baseline levels, excluding fatigue or hair loss).
- Pregnant or breastfeeding women.
- Severe or uncontrolled systemic diseases, including:
- Major, symptomatic arrhythmias or significant ECG abnormalities (e.g., complete left bundle branch block, second-degree or higher heart block, or ventricular arrhythmias).
- Unstable angina or congestive heart failure (NYHA class ≥ 2).
- Any arterial thrombotic or embolic events within 6 months before enrollment (e.g., myocardial infarction, cerebrovascular accident, transient ischemic attack).
- Active or uncontrolled infections requiring systemic treatment.
- Severe psychiatric disorders affecting study participation.
- Any medical history, laboratory abnormality, or condition that may:
- Interfere with study results.
- Affect patient participation.
- Pose an unacceptable risk as determined by the investigator.
- Women of childbearing potential without a negative pregnancy test prior to study entry.
- Known allergy or hypersensitivity to [18F]AlF-NOTA-PCP2 or any component of the radiopharmaceutical.
Quoted from ClinicalTrials.gov, NCT06690216, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06690216, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.